PALO ALTO, Calif., Nov. 02, 2015 (GLOBE NEWSWIRE) -- Open Monoclonal Technology, Inc. (OMT) today announced a license that provides Seattle Genetics, Inc. with access to OMT’s proprietary OmniRat®, OmniMouse® and OmniFlic™ human antibody generation platforms. Seattle Genetics becomes OMT’s 19th partner globally.
Dr. Roland Buelow, OMT founder and CEO, said, “Seattle Genetics is an established leader in the field of antibody-drug-conjugates. We are pleased to provide the company with access to OMT’s human antibody generation technologies to accelerate their continued efforts to develop and commercialize innovative antibody-based therapies for cancer.”
About OMT Group
Open Monoclonal Technology, Inc. (OMT), OMT Therapeutics, Inc. (OMTT), and Recombinant Antibody Technology, Ltd. (RAT) are leaders in genetic engineering of animals for the generation of mono-, bi- and poly-specific human therapeutic antibodies, naturally optimized human antibodies®, and the only group in the world with four transgenic animal platforms.
OmniRat® is the industry’s first human monoclonal antibody technology based on rats. It has a complete immune system with a diverse antibody repertoire and generates antibodies with human idiotypes as well as wild-type animals make rat antibodies. OmniMouse® is a transgenic mouse that complements OmniRat and expands epitope coverage. OmniFlic™ is an engineered rat with a fixed light chain for development of bispecific, fully human antibodies. Full-length human antibodies from these three animals are called OmniAb™. UniRat™ is the first transgenic rat generating human UniAb™ heavy chain-only antibodies and nanobodies for polyspecific applications.
All four platforms use patented technology, have broad freedom to operate and deliver fully human antibodies with high affinity, specificity, expression, solubility and stability. Animals are hosted in master colonies globally by Charles River Labs and Taconic with backups at Genentech and Roche. OmniAb and UniAb antibody discovery services are available via Antibody Solutions, OMTT and Sage Labs in the US, Aldevron and Taconic in Europe and WuXi AppTec in Asia.
OmniAb and UniAb antibodies are available for all applications, indications and territories. Current partners include Amgen, ARMO, Berlin-Brandenburg Center for Regenerative Therapies, Caltech, Celgene, Chugai, Five Prime, Genmab, Genentech, Gloria, HanAll, Janssen, Merck KGaA, Pfizer, Roche, Seattle Genetics, Symphogen, University of Nottingham and some undisclosed biotech and pharmaceutical companies.
Source:Open Monoclonal Technology, Inc.